User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Management of glucocorticoid-induced osteoporosis.

Primary tabs

Rizzoli, R Adachi, J D Cooper, C Dere, W Devogelaer, Jean-Pierre [UCL] Reginster, J Y

This review summarizes the available evidence-based data that form the basis for therapeutic intervention and covers the current status of glucocorticoid-induced osteoporosis (GIOP) management, regulatory requirements, and risk-assessment options. Glucocorticoids are known to cause bone loss and fractures, yet many patients receiving or initiating glucocorticoid therapy are not appropriately evaluated and treated. An European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis workshop was convened to discuss GIOP management and to provide a report by a panel of experts. An expert panel reviewed the available studies that discussed approved therapeutic agents, focusing on randomized and controlled clinical trials reporting on bone mineral density and/or fracture risk of at least 48 weeks' duration. There is no evidence that GIOP and postmenopausal osteoporosis respond differently to treatments. The FRAX algorithm can be adjusted according to glucocorticoid dose. Available antiosteoporotic therapies such as bisphosphonates and teriparatide are efficacious in GIOP management. Several other agents approved for the treatment of postmenopausal osteoporosis may become available for GIOP. It is advised to stop antiosteoporotic treatment after glucocorticoid cessation, unless the patient remains at increased risk of fracture. Calcium and vitamin D supplementation as an osteoporosis-prevention measure is less effective than specific antiosteoporotic treatment. Fracture end-point studies and additional studies investigating specific subpopulations (pediatric, premenopausal, or elderly patients) would strengthen the evidence base and facilitate the development of intervention thresholds and treatment guidelines.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2012
Language Anglais
Journal information "Calcified Tissue International" - Vol. 91, no.4, p. 225-43 (2012)
Peer reviewed yes
Publisher Springer New York LLC ((United States) New York)
issn 0171-967X
e-issn 1432-0827
Publication status Publié
Affiliations UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales
UCL - (SLuc) Service de rhumatologie
Links
  1. Canalis E., Mazziotti G., Giustina A., Bilezikian J. P., Glucocorticoid-induced osteoporosis: pathophysiology and therapy, 10.1007/s00198-007-0394-0
  2. Staa T. P. van, Staa T. P. van, Staa T. P. van, Leufkens H. G. M., Cooper C., The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis, 10.1007/s001980200108
  3. Compston Juliet E., Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis, 10.1007/s11926-007-0026-x
  4. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost–utility analysis. Health Technol Assess 11(7):iii–iv, ix–xi, 1–231
  5. Walsh L J, Wong C A, Pringle M, Tattersfield A E, Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study, 10.1136/bmj.313.7053.344
  6. van Staa T.P., Use of oral corticosteroids in the United Kingdom, 10.1093/qjmed/93.2.105
  7. Díez-Pérez Adolfo, Hooven Frederick H., Adachi Jonathan D., Adami Silvano, Anderson Frederick A., Boonen Steven, Chapurlat Roland, Compston Juliet E., Cooper Cyrus, Delmas Pierre, Greenspan Susan L., LaCroix Andrea Z., Lindsay Robert, Netelenbos J. Coen, Pfeilschifter Johannes, Roux Christian, Saag Kenneth G., Sambrook Philip, Silverman Stuart, Siris Ethel S., Watts Nelson B., Nika Grigor, Gehlbach Stephen H., Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW), 10.1016/j.bone.2011.05.007
  8. Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33(8):1651–1657
  9. Gudbjornsson B, Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice, 10.1136/ard.61.1.32
  10. van Staa T. P., Leufkens H. G. M., Abenhaim L., Zhang B., Cooper C., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, 10.1093/rheumatology/39.12.1383
  11. Steinbuch Michael, Youket Thomas E., Cohen Stanley, Oral glucocorticoid use is associated with an increased risk of fracture, 10.1007/s00198-003-1548-3
  12. Van Staa T. P., Leufkens H. G. M., Abenhaim L., Zhang B., Cooper C., Use of Oral Corticosteroids and Risk of Fractures, 10.1359/jbmr.2000.15.6.993
  13. Kanis John A, Johansson Helena, Oden Anders, Johnell Olof, de Laet Chris, Melton L Joseph, Tenenhouse Alan, Reeve Jonathan, Silman Alan J, Pols Huibert AP, Eisman John A, McCloskey Eugene V, Mellstrom Dan, A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk, 10.1359/jbmr.040134
  14. Kroger H, Honkanen R, Saarikoski S, Alhava E, Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study., 10.1136/ard.53.1.18
  15. Adachi Jonathan D., Papaioannou Alexandra, In whom and how to prevent glucocorticoid-induced osteoporosis, 10.1016/j.berh.2005.07.002
  16. Van Staa T. P., Leufkens H. G. M., Cooper C., Use of Inhaled Corticosteroids and Risk of Fractures, 10.1359/jbmr.2001.16.3.581
  17. Leib Edward S., Saag Kenneth G., Adachi Jonathan D., Geusens Piet P., Binkley Neil, McCloskey Eugene V., Hans Didier B., Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture, 10.1016/j.jocd.2011.05.014
  18. Etminan Mahyar, Sadatsafavi Mohsen, Ganjizadeh Zavareh Saeedreza, Takkouche Bahi, FitzGerald J Mark, Inhaled Corticosteroids and the Risk of Fractures in Older Adults : A Systematic Review and Meta-Analysis, 10.2165/00002018-200831050-00005
  19. Wlodarczyk John H., Gibson Peter G., Caeser Manfred, Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review, 10.1016/s1081-1206(10)60400-0
  20. van Staa Tjeerd-Pieter, Bishop Nick, Leufkens Hubert G. M., Cooper Cyrus, Are inhaled corticosteroids associated with an increased risk of fracture in children?, 10.1007/s00198-004-1606-5
  21. BIJLSMA J. W. J., DUURSMA S. A., BOSCH R., RAYMAKERS J. A., HUBER-BRUNING O., ACUTE CHANGES IN CALCIUM AND BONE METABOLISM DURING METHYLPREDNISOLONE PULSE THERAPY IN RHEUMATOID ARTHRITIS, 10.1093/rheumatology/27.3.215
  22. Bijlsma J W, Duursma S A, Huber-Bruning O, Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis., 10.1136/ard.45.9.757
  23. Van Der Veen M. J., Bijlsma J. W. J., Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis, 10.1007/bf02207199
  24. Rizzoli R, von Tscharner V, Fleisch H, Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells, 10.1042/bj2370447
  25. Leonard Mary B., Feldman Harold I., Shults Justine, Zemel Babette S., Foster Bethany J., Stallings Virginia A., Long-Term, High-Dose Glucocorticoids and Bone Mineral Content in Childhood Glucocorticoid-Sensitive Nephrotic Syndrome, 10.1056/nejmoa040367
  26. McEVOY CHARLENE E., ENSRUD KRISTINE E., BENDER EARL, GENANT HARRY K., YU WEI, GRIFFITH JAYNE M., NIEWOEHNER DENNIS E., Association between Corticosteroid Use and Vertebral Fractures in Older Men with Chronic Obstructive Pulmonary Disease, 10.1164/ajrccm.157.3.9703080
  27. De Vries Frank, Bracke Madelon, Leufkens Hubert G. M., Lammers Jan-Willem J., Cooper Cyrus, Van Staa Tjeerd P., Fracture risk with intermittent high-dose oral glucocorticoid therapy, 10.1002/art.22294
  28. Compston Juliet, Management of glucocorticoid-induced osteoporosis, 10.1038/nrrheum.2009.259
  29. Vestergaard Peter, Rejnmark Lars, Mosekilde Leif, Fracture Risk Associated with Different Types of Oral Corticosteroids and Effect of Termination of Corticosteroids on the Risk of Fractures, 10.1007/s00223-008-9124-7
  30. Laan Roland F. J. M., Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis : A Randomized, Controlled Study, 10.7326/0003-4819-119-10-199311150-00001
  31. Ton Francine N, Gunawardene Samantha C, Lee Hang, Neer Robert M, Effects of Low-Dose Prednisone on Bone Metabolism, 10.1359/jbmr.041125
  32. Weinstein R S, Jilka R L, Parfitt A M, Manolagas S C, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone., 10.1172/jci2799
  33. Weinstein RS (2009) Glucocorticoid-induced osteoporosis. In: MR ASB (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. John Wiley & Sons, Hoboken, NJ. doi: 10.1002/9780470623992.ch58
  34. Rochefort G. Y., Pallu S., Benhamou C. L., Osteocyte: the unrecognized side of bone tissue, 10.1007/s00198-010-1194-5
  35. den Uyl Debby, Bultink Irene E. M., Lems Willem F., Advances in Glucocorticoid-Induced Osteoporosis, 10.1007/s11926-011-0173-y
  36. Hayashi Kumi, Yamaguchi Toru, Yano Shozo, Kanazawa Ippei, Yamauchi Mika, Yamamoto Masahiro, Sugimoto Toshitsugu, BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis, 10.1016/j.bbrc.2008.12.035
  37. Yao Wei, Cheng Zhiqiang, Busse Cheryl, Pham Aaron, Nakamura Mary C., Lane Nancy E., Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice, 10.1002/art.23454
  38. Hofbauer Lorenz C., Rauner Martina, Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells, 10.1210/me.2009-0069
  39. Weinstein R. S., Apoptosis of Osteocytes in Glucocorticoid-Induced Osteonecrosis of the Hip, 10.1210/jc.85.8.2907
  40. Cooper Mark S., Rabbitt Elizabeth H., Goddard Philippa E., Bartlett William A., Hewison Martin, Stewart Paul M., Osteoblastic 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure, 10.1359/jbmr.2002.17.6.979
  41. Compston J., Reid D. M., Boisdron J., Brandi M.-L., Burlet N., Cahall D., Delmas P. D., Dere W., Devogelaer J.-P., Fitzpatrick L. A., Flamion B., Goel N., Korte S., Laslop A., Mitlak B., Ormarsdottir S., Ringe J., Rizzoli R., Tsouderos Y., Van Staa T., Reginster J.-Y., Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science, 10.1007/s00198-008-0670-7
  42. Kanis J. A., Johnell O., Oden A., Johansson H., McCloskey E., FRAX™ and the assessment of fracture probability in men and women from the UK, 10.1007/s00198-007-0543-5
  43. Kanis J. A., McCloskey E. V., Johansson H., Strom O., Borgstrom F., Oden A., , Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK, 10.1007/s00198-008-0712-1
  44. Kanis J. A., Johansson H., Oden A., McCloskey E. V., Guidance for the adjustment of FRAX according to the dose of glucocorticoids, 10.1007/s00198-010-1524-7
  45. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the European Union. Arch Osteoporos. doi: 10.1007/s11657-011-0060-1
  46. Grossman Jennifer M., Gordon Rebecca, Ranganath Veena K., Deal Chad, Caplan Liron, Chen Weiling, Curtis Jeffrey R., Furst Daniel E., McMahon Maureen, Patkar Nivedita M., Volkmann Elizabeth, Saag Kenneth G., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, 10.1002/acr.20295
  47. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; for the Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. doi: 10.1007/s00198-012-1958-1
  48. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Doc. ref. CPMP/EWP/552/95 Rev. 2. European Medicines Agency, London
  49. Committee for Medicinal Products for Human Use (CHMP) (2010) Concept paper on the need for an addendum on the clinical investigation of medicinal products intended for treatment of glucocorticoid-induced osteoporosis. Doc. ref. EMA/CHMP/EWP/15912/2010. European Medicines Agency, London
  50. World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva, Switzerland
  51. Compston Juliet, Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis? : Steroid-induced osteoporosis, 10.1111/j.1365-2265.2011.03994.x
  52. Cohen Stanley, Levy Robert M., Keller Michael, Boling Eugene, Emkey Ronald D., Greenwald Maria, Zizic Thomas M., Wallach Stanley, Sewell Kathryn L., Lukert Barbara P., Axelrod Douglas W., Chines Arkadi A., Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, 10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k
  53. Saag Kenneth G., Emkey Ronald, Schnitzer Thomas J., Brown Jacques P., Hawkins Federico, Goemaere Stefan, Thamsborg Gorm, Liberman Uri A., Delmas Pierre D., Malice Marie-Pierre, Czachur Michelle, Daifotis Anastasia G., Lane Nancy, Correa-Rotter Ricardo, Yanover Melissa, Westhovens Rene, Epstein Sol, Adachi Jonathan D., Poubelle Patrice, Melo-Gomes Jose, Rodriguez-Portales Jose A., Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis, 10.1056/nejm199807303390502
  54. Wallach S., Cohen S., Reid D. M., Hughes R. A., Hosking D. J., Laan R. F., Doherty S. M., Maricic M., Rosen C., Brown J., Barton I., Chines A. A., Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy, 10.1007/s002230001146
  55. Langdahl B. L., Marin F., Shane E., Dobnig H., Zanchetta J. R., Maricic M., Krohn K., See K., Warner M. R., Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status, 10.1007/s00198-009-0917-y
  56. Shaw N. J, Management of osteoporosis in children, 10.1530/eje-08-0282
  57. van Staa TP, Cooper C, Leufkens Hgm, Bishop N, Children and the Risk of Fractures Caused by Oral Corticosteroids, 10.1359/jbmr.2003.18.5.913
  58. Marini Joan C., Do Bisphosphonates Make Children's Bones Better or Brittle?, 10.1056/nejmp038103
  59. DORE R. K., How to prevent glucocorticoid-induced osteoporosis, 10.3949/ccjm.77a.10003
  60. Bianchi Maria, Glucorticoids and Bone: Some General Remarks and Some Special Observations in Pediatric Patients, 10.1007/s00223-001-0043-0
  61. Inoue Yuzaburo, Shimojo Naoki, Suzuki Shuichi, Arima Takayasu, Tomiita Minako, Minagawa Masanori, Kohno Yoichi, Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases, 10.1007/s10067-008-0864-6
  62. Nakhla Meranda, Denker Andrew E., Connor James D., Carpenter Thomas O., Walson Philip D., Porras Arturo G., Matthews Catherine Z., Larson Patrick, Freeman Amanda, Wagner John A., Ward Leanne M., Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children, 10.1016/j.clinthera.2011.09.001
  63. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 4: CD005324
  64. Devogelaer Jean-Pierre, Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach, 10.1016/j.rdc.2006.09.001
  65. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952
  66. Amin Shreyasee, LaValley Michael P., Simms Robert W., Felson David T., The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach, 10.1002/1529-0131(199908)42:8<1740::aid-anr25>3.0.co;2-e
  67. Adachi Jonathan D., Bensen William G., Brown Jacques, Hanley David, Hodsman Anthony, Josse Robert, Kendler David L., Lentle Brian, Olszynski Wojciech, Ste.-Marie Louis-George, Tenenhouse Alan, Chines Arkadi A., Jovaisas Algis, Sturtridge William C., Anastassiades Tassos P., Hanly John G., Pope Janet E., Dias Reginald, Horowitz Zebulun D., Pack Simon, Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis, 10.1056/nejm199708073370603
  68. Sambrook Philip, Birmingham Joan, Kelly Paul, Kempler Susan, Nguyen Tuan, Pocock Nicholas, Eisman John, Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin, 10.1056/nejm199306173282404
  69. Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M (1996) Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc 28(6):3485–3487
  70. McDonald C. F., Zebaze R. M. D., Seeman E., Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial, 10.1007/s00198-006-0158-2
  71. de Nijs Ron N.J., Jacobs Johannes W.G., Lems Willem F., Laan Roland F.J., Algra Ale, Huisman Anne-Margriet, Buskens Erik, de Laet Chris E.D., Oostveen Ans C.M., Geusens Piet P.M.M., Bruyn George A.W., Dijkmans Ben A.C., Bijlsma Johannes W.J., Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis, 10.1056/nejmoa053569
  72. de Nijs R. N. J., Jacobs J. W. G., Algra A., Lems W. F., Bijlsma J. W. J., Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies, 10.1007/s00198-004-1614-5
  73. Adachi Jonathan D., Saag Kenneth G., Delmas Pierre D., Liberman Uri A., Emkey Ronald D., Seeman Ego, Lane Nancy E., Kaufman Jean-Marc, Poubelle Patrice E. E., Hawkins Federico, Correa-Rotter Ricardo, Menkes Charles-Joel, Rodriguez-Portales Jose A., Schnitzer Thomas J., Block Joel A., Wing Jeffrey, McIlwain Harris H., Westhovens Rene, Brown Jacques, Melo-Gomes Jose A., Gruber Barry L., Yanover Melissa J., Leite Maria Odette R., Siminoski Kerry G., Nevitt Michael C., Sharp John T., Malice Marie-Pierre, Dumortier Thomas, Czachur Michelle, Carofano Wendy, Daifotis Anastasia, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial, 10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w
  74. Reid David M., Hughes Rodney A., Laan Roland F. J. M., Sacco-Gibson Nancy A., Wenderoth Dietrich H., Adami Silvano, Eusebio Rachelle A., Devogelaer Jean-Pierre, Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial, 10.1359/jbmr.2000.15.6.1006
  75. Jenkins, K.E Walker-Bone, A Wood, F E.A, The Prevention of Corticosteroid-induced Bone Loss with Intermittent Cyclical Etidronate, 10.1080/03009749950154211
  76. Roux C., Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss, 10.1210/jc.83.4.1128
  77. Geusens P., Dequeker J., Vanhoof J., Stalmans R., Boonen S., Joly J., Nijs J., Raus J., Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study, 10.1136/ard.57.12.724
  78. Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C, A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment, 10.1136/thx.53.5.351
  79. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155
  80. Shane Elizabeth, Addesso Vicki, Namerow Pearila B., McMahon Donald J., Lo Shaw-Hwa, Staron Ronald B., Zucker Mark, Pardi Susan, Maybaum Simon, Mancini Donna, Alendronate versus Calcitriol for the Prevention of Bone Loss after Cardiac Transplantation, 10.1056/nejmoa035617
  81. Takeda Seiji, Kaneoka Hidetoshi, Saito Takao, Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol, 10.1007/s10165-008-0055-y
  82. Sambrook Philip N, Kotowicz Mark, Nash Peter, Styles Colin B, Naganathan Vasi, Henderson-Briffa Kathy N, Eisman John A, Nicholson Geoff C, Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: A Comparison of Calcitriol, Vitamin D Plus Calcium, and Alendronate Plus Calcium, 10.1359/jbmr.2003.18.5.919
  83. Okada Yosuke, Nawata Masao, Nakayamada Shingo, Saito Kazuyoshi, Tanaka Yoshiya, Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy, 10.3899/jrheum.080168
  84. Reid D.M., Adami S., Devogelaer J.-P., Chines A.A., Risedronate Increases Bone Density and Reduces Vertebral Fracture Risk Within One Year in Men on Corticosteroid Therapy, 10.1007/s00223-001-1060-8
  85. Boutsen Y., Jamart J., Esselinckx W., Stoffel M., Devogelaer J.-P., Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intermittent Intravenous Pamidronate: A Randomized Trial, 10.1007/s002239900334
  86. Boutsen Y., Jamart J., Esselinckx W., Devogelaer J. P., Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1-Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone, 10.1359/jbmr.2001.16.1.104
  87. Reid David M, Devogelaer Jean-Pierre, Saag Kenneth, Roux Christian, Lau Chak-Sing, Reginster Jean-Yves, Papanastasiou Philemon, Ferreira Alberto, Hartl Florian, Fashola Taiwo, Mesenbrink Peter, Sambrook Philip N, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, 10.1016/s0140-6736(09)60250-6
  88. Ringe J. D., Dorst A., Faber H., Ibach K., Sorenson F., Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study, 10.1007/s00198-003-1425-0
  89. Hollick R. J., Reid D. M., Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties, 10.1258/mi.2011.011014
  90. DEVOGELAER J.-P., ADLER R. A., RECKNOR C., SEE K., WARNER M. R., WONG M., KROHN K., Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis, 10.3899/jrheum.090411
  91. Saag Kenneth G., Shane Elizabeth, Boonen Steven, Marín Fernando, Donley David W., Taylor Kathleen A., Dalsky Gail P., Marcus Robert, Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, 10.1056/nejmoa071408
  92. Saag Kenneth G., Zanchetta Jose R., Devogelaer Jean-Pierre, Adler Robert A., Eastell Richard, See Kyoungah, Krege John H., Krohn Kelly, Warner Margaret R., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial : Teriparatide Versus Alendronate in Glucocorticoid-Induced OP, 10.1002/art.24879
  93. Neer Robert M., Arnaud Claude D., Zanchetta Jose R., Prince Richard, Gaich Gregory A., Reginster Jean-Yves, Hodsman Anthony B., Eriksen Erik F., Ish-Shalom Sophia, Genant Harry K., Wang Ouhong, Mellström Dan, Oefjord Erik S., Marcinowska-Suchowierska Ewa, Salmi Jorma, Mulder Henk, Halse Johan, Sawicki Andrzej Z., Mitlak Bruce H., Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, 10.1056/nejm200105103441904
  94. Lane N E, Sanchez S, Modin G W, Genant H K, Pierini E, Arnaud C D, Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial., 10.1172/jci3914
  95. Rizzoli René, Reginster Jean-Yves, Boonen Steven, Bréart Gérard, Diez-Perez Adolfo, Felsenberg Dieter, Kaufman Jean-Marc, Kanis John A., Cooper Cyrus, Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis, 10.1007/s00223-011-9499-8
  96. Delmas Pierre D., Bjarnason Nina H., Mitlak Bruce H., Ravoux Anne-Catherine, Shah Aarti S., Huster William J., Draper Michael, Christiansen Claus, Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women, 10.1056/nejm199712043372301
  97. Ettinger Bruce, Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial, 10.1001/jama.282.7.637
  98. Mok C. C., Ying K. Y., To C. H., Ho L. Y., Yu K. L., Lee H. K., Ma K. M., Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial, 10.1136/ard.2010.143453
  99. Meunier Pierre J., Roux Christian, Seeman Ego, Ortolani Sergio, Badurski Janusz E., Spector Tim D., Cannata Jorge, Balogh Adam, Lemmel Ernst-Martin, Pors-Nielsen Stig, Rizzoli René, Genant Harry K., Reginster Jean-Yves, The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis, 10.1056/nejmoa022436
  100. Reginster J. Y., Seeman E., De Vernejoul M. C., Adami S., Compston J., Phenekos C., Devogelaer J. P., Curiel M. Diaz, Sawicki A., Goemaere S., Sorensen O. H., Felsenberg D., Meunier P. J., Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study, 10.1210/jc.2004-1774
  101. Sun P., Cai D. H., Li Q. N., Chen H., Deng W. M., He L., Yang L., Effects of Alendronate and Strontium Ranelate on Cancellous and Cortical Bone Mass in Glucocorticoid-Treated Adult Rats, 10.1007/s00223-010-9363-2
  102. Lacey D.L, Timms E, Tan H.-L, Kelley M.J, Dunstan C.R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y.-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W.J, Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, 10.1016/s0092-8674(00)81569-x
  103. Simonet W.S, Lacey D.L, Dunstan C.R, Kelley M, Chang M.-S, Lüthy R, Nguyen H.Q, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H.-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes T.M, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle W.J, Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, 10.1016/s0092-8674(00)80209-3
  104. Cummings Steven R., Martin Javier San, McClung Michael R., Siris Ethel S., Eastell Richard, Reid Ian R., Delmas Pierre, Zoog Holly B., Austin Matt, Wang Andrea, Kutilek Stepan, Adami Silvano, Zanchetta Jose, Libanati Cesar, Siddhanti Suresh, Christiansen Claus, Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, 10.1056/nejmoa0809493
  105. Hofbauer L. C., Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis, 10.1210/en.140.10.4382
  106. Sivagurunathan Sutharshani, Muir Meloni M, Brennan Tara C, Seale J Paul, Mason Rebecca S, Influence of Glucocorticoids on Human Osteoclast Generation and Activity, 10.1359/jbmr.041233
  107. Vidal N., Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids, 10.1677/joe.0.1590191
  108. Weinstein Robert S., O'Brien Charles A., Almeida Maria, Zhao Haibo, Roberson Paula K., Jilka Robert L., Manolagas Stavros C., Osteoprotegerin Prevents Glucocorticoid-Induced Osteocyte Apoptosis in Mice, 10.1210/en.2011-0170
  109. Hofbauer Lorenz C., Zeitz Ute, Schoppet Michael, Skalicky Monika, Schüler Christiane, Stolina Marina, Kostenuik Paul J., Erben Reinhold G., Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL, 10.1002/art.24445
  110. Nakashima Tomoki, Hayashi Mikihito, Fukunaga Takanobu, Kurata Kosaku, Oh-hora Masatsugu, Feng Jian Q, Bonewald Lynda F, Kodama Tatsuhiko, Wutz Anton, Wagner Erwin F, Penninger Josef M, Takayanagi Hiroshi, Evidence for osteocyte regulation of bone homeostasis through RANKL expression, 10.1038/nm.2452
  111. Xiong Jinhu, Onal Melda, Jilka Robert L, Weinstein Robert S, Manolagas Stavros C, O'Brien Charles A, Matrix-embedded cells control osteoclast formation, 10.1038/nm.2448
  112. Cohen Stanley B., Dore Robin K., Lane Nancy E., Ory Peter A., Peterfy Charles G., Sharp John T., van der Heijde Désirée, Zhou Lifen, Tsuji Wayne, Newmark Richard, , Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, 10.1002/art.23417
  113. Dore R. K., Cohen S. B., Lane N. E., Palmer W., Shergy W., Zhou L., Wang H., Tsuji W., Newmark R., , Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates, 10.1136/ard.2009.112920
  114. Jia J., Yao W., Guan M., Dai W., Shahnazari M., Kar R., Bonewald L., Jiang J. X., Lane N. E., Glucocorticoid dose determines osteocyte cell fate, 10.1096/fj.11-182519
  115. Stoch SA, Wagner JA, Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy, 10.1038/sj.clpt.6100450
  116. Marenzana M., Greenslade K., Eddleston A., Okoye R., Marshall D., Moore A., Robinson M. K., Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone, 10.1002/art.30385
  117. van Lierop Antoon HJM, Hamdy Neveen AT, Papapoulos Socrates E, Glucocorticoids are not always deleterious for bone, 10.1002/jbmr.151
  118. Gerber A. N., Masuno K., Diamond M. I., Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening, 10.1073/pnas.0812308106
  119. Rauch A., Gossye V., Bracke D., Gevaert E., Jacques P., Van Beneden K., Vandooren B., Rauner M., Hofbauer L. C., Haegeman G., Elewaut D., Tuckermann J. P., De Bosscher K., An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation, 10.1096/fj.10-173393
  120. Morrison Nigel, Eisman John, Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter, 10.1002/jbmr.5650080810
  121. COOPER Mark S., Sensitivity of bone to glucocorticoids, 10.1042/cs20040070
Bibliographic reference Rizzoli, R ; Adachi, J D ; Cooper, C ; Dere, W ; Devogelaer, Jean-Pierre ; et. al. Management of glucocorticoid-induced osteoporosis.. In: Calcified Tissue International, Vol. 91, no.4, p. 225-43 (2012)
Permanent URL http://hdl.handle.net/2078.1/124536